Effect of renal denervation on long-term outcomes in patients with resistant hypertension

被引：0
作者：
Bo Liang
Yi Liang
Rui Li
Ning Gu
机构：
[1] Nanjing University of Chinese Medicine,
[2] Southwest Medical University,undefined
[3] Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,undefined
来源：
Cardiovascular Diabetology | / 20卷
关键词：
Hypertension; Renal denervation; Resistant hypertension; Intervention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Increasing studies strongly prove that renal denervation, a minimally invasive surgery, is a promising new non-drug treatment method that can effectively control blood pressure in patients with resistant hypertension, but the evaluation of the long-term blood pressure control effect of renal denervation for resistant hypertension is still lacking. Here, we critically review current long-term follow-up data about the use of renal denervation for RH to comprehensively evaluate the effectiveness of renal denervation for RH, and to provide practical guidance for practitioners who are establishing a renal denervation service. Limited by the current research, many problems need to be solved before renal denervation is applied to RH. In addition, ambulatory blood pressure should be the first choice for the evaluation of blood pressure. Finally, the continuous antihypertensive effect of renal denervation in different renal denervation systems also needs to be strictly compared.
引用
收藏
相关论文
共 352 条
[1]  
Whelton PK(2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Hypertension 71 1269-1324
[2]  
Carey RM(2019)Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering J Clin Hypertens 21 825-34
[3]  
Aronow WS(2019)Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES) BMC Nephrol 20 138-64
[4]  
Casey DE(2020)Impact of changes to national hypertension guidelines on hypertension management and outcomes in the United Kingdom Hypertension 75 356-5
[5]  
Collins KJ(2017)Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995–2015 BMJ. 358 3984-72
[6]  
Dennison Himmelfarb C(2018)Resistant hypertension: time to consider the best fifth anti-hypertensive treatment Curr Hypertens Rep 20 67-100
[7]  
De Palma SM(2019)Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study) Cardiovasc Diabetol 18 110-82
[8]  
Gidding S(2019)Renal denervation for hypertension: what is needed, and what is next Eur Heart J 40 3483-81
[9]  
Jamerson KA(2020)Renal denervation for resistant hypertension: where do we stand? Curr Hypertens Rep 22 83-1229
[10]  
Jones DW(2014)Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system Hypertension 64 565-368
12345678910